Determination of Nadir growth hormone concentration cutoff in patients with acromegaly

Irina Bancos, Alicia Algeciras-Schimnich, Whitney Woodmansee, Alison Cullinane, Leslie Donato, Todd Nippoldt, Neena Natt, Dana Erickson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The purpose of this study was to define an appropriate nadir growth hormone (nGH) cutoff for patients with acromegaly in remission using the Access Ultrasensitive human growth hormone (hGH) assay (Beckman Coulter, Brea, CA).Methods: This cross-sectional study included 55 acromegalic subjects and 41 healthy adult volunteers. All subjects underwent oral glucose tolerance testing (OGTT) for growth hormones (GHs). An optimal cutoff for nGH for patients with active disease versus those in remission was determined using receiver-operating curve analysis.Results: The nGH of 0.53 ng/mL revealed a sensitivity of 97% (95% confidence interval [CI], 83-100%) and a specificity of 100% (95% CI, 82-100%). All 22 patients with acromegaly in remission suppressed GH to <1 ng/mL, 20/22 (91%) suppressed to <0.4 ng/mL, and 19/22 (86%) of subjects suppressed to <0.3 ng/mL (the maximum nGH measured in our healthy volunteer group).Conclusion: When using the Access Ultrasensitive hGH assay for OGTT, a cutoff of 0.53 ng/mL was found to most accurately differentiate patients with acromegaly in remission from those with active disease.

Original languageEnglish (US)
Pages (from-to)937-945
Number of pages9
JournalEndocrine Practice
Volume19
Issue number6
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Acromegaly
Growth Hormone
Human Growth Hormone
Glucose Tolerance Test
Healthy Volunteers
Confidence Intervals
Cross-Sectional Studies

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Bancos, I., Algeciras-Schimnich, A., Woodmansee, W., Cullinane, A., Donato, L., Nippoldt, T., ... Erickson, D. (2013). Determination of Nadir growth hormone concentration cutoff in patients with acromegaly. Endocrine Practice, 19(6), 937-945. https://doi.org/10.4158/EP12435.OR

Determination of Nadir growth hormone concentration cutoff in patients with acromegaly. / Bancos, Irina; Algeciras-Schimnich, Alicia; Woodmansee, Whitney; Cullinane, Alison; Donato, Leslie; Nippoldt, Todd; Natt, Neena; Erickson, Dana.

In: Endocrine Practice, Vol. 19, No. 6, 01.11.2013, p. 937-945.

Research output: Contribution to journalArticle

Bancos, I, Algeciras-Schimnich, A, Woodmansee, W, Cullinane, A, Donato, L, Nippoldt, T, Natt, N & Erickson, D 2013, 'Determination of Nadir growth hormone concentration cutoff in patients with acromegaly', Endocrine Practice, vol. 19, no. 6, pp. 937-945. https://doi.org/10.4158/EP12435.OR
Bancos I, Algeciras-Schimnich A, Woodmansee W, Cullinane A, Donato L, Nippoldt T et al. Determination of Nadir growth hormone concentration cutoff in patients with acromegaly. Endocrine Practice. 2013 Nov 1;19(6):937-945. https://doi.org/10.4158/EP12435.OR
Bancos, Irina ; Algeciras-Schimnich, Alicia ; Woodmansee, Whitney ; Cullinane, Alison ; Donato, Leslie ; Nippoldt, Todd ; Natt, Neena ; Erickson, Dana. / Determination of Nadir growth hormone concentration cutoff in patients with acromegaly. In: Endocrine Practice. 2013 ; Vol. 19, No. 6. pp. 937-945.
@article{49b743efe535491bb212757b489a0801,
title = "Determination of Nadir growth hormone concentration cutoff in patients with acromegaly",
abstract = "Objective: The purpose of this study was to define an appropriate nadir growth hormone (nGH) cutoff for patients with acromegaly in remission using the Access Ultrasensitive human growth hormone (hGH) assay (Beckman Coulter, Brea, CA).Methods: This cross-sectional study included 55 acromegalic subjects and 41 healthy adult volunteers. All subjects underwent oral glucose tolerance testing (OGTT) for growth hormones (GHs). An optimal cutoff for nGH for patients with active disease versus those in remission was determined using receiver-operating curve analysis.Results: The nGH of 0.53 ng/mL revealed a sensitivity of 97{\%} (95{\%} confidence interval [CI], 83-100{\%}) and a specificity of 100{\%} (95{\%} CI, 82-100{\%}). All 22 patients with acromegaly in remission suppressed GH to <1 ng/mL, 20/22 (91{\%}) suppressed to <0.4 ng/mL, and 19/22 (86{\%}) of subjects suppressed to <0.3 ng/mL (the maximum nGH measured in our healthy volunteer group).Conclusion: When using the Access Ultrasensitive hGH assay for OGTT, a cutoff of 0.53 ng/mL was found to most accurately differentiate patients with acromegaly in remission from those with active disease.",
author = "Irina Bancos and Alicia Algeciras-Schimnich and Whitney Woodmansee and Alison Cullinane and Leslie Donato and Todd Nippoldt and Neena Natt and Dana Erickson",
year = "2013",
month = "11",
day = "1",
doi = "10.4158/EP12435.OR",
language = "English (US)",
volume = "19",
pages = "937--945",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "6",

}

TY - JOUR

T1 - Determination of Nadir growth hormone concentration cutoff in patients with acromegaly

AU - Bancos, Irina

AU - Algeciras-Schimnich, Alicia

AU - Woodmansee, Whitney

AU - Cullinane, Alison

AU - Donato, Leslie

AU - Nippoldt, Todd

AU - Natt, Neena

AU - Erickson, Dana

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Objective: The purpose of this study was to define an appropriate nadir growth hormone (nGH) cutoff for patients with acromegaly in remission using the Access Ultrasensitive human growth hormone (hGH) assay (Beckman Coulter, Brea, CA).Methods: This cross-sectional study included 55 acromegalic subjects and 41 healthy adult volunteers. All subjects underwent oral glucose tolerance testing (OGTT) for growth hormones (GHs). An optimal cutoff for nGH for patients with active disease versus those in remission was determined using receiver-operating curve analysis.Results: The nGH of 0.53 ng/mL revealed a sensitivity of 97% (95% confidence interval [CI], 83-100%) and a specificity of 100% (95% CI, 82-100%). All 22 patients with acromegaly in remission suppressed GH to <1 ng/mL, 20/22 (91%) suppressed to <0.4 ng/mL, and 19/22 (86%) of subjects suppressed to <0.3 ng/mL (the maximum nGH measured in our healthy volunteer group).Conclusion: When using the Access Ultrasensitive hGH assay for OGTT, a cutoff of 0.53 ng/mL was found to most accurately differentiate patients with acromegaly in remission from those with active disease.

AB - Objective: The purpose of this study was to define an appropriate nadir growth hormone (nGH) cutoff for patients with acromegaly in remission using the Access Ultrasensitive human growth hormone (hGH) assay (Beckman Coulter, Brea, CA).Methods: This cross-sectional study included 55 acromegalic subjects and 41 healthy adult volunteers. All subjects underwent oral glucose tolerance testing (OGTT) for growth hormones (GHs). An optimal cutoff for nGH for patients with active disease versus those in remission was determined using receiver-operating curve analysis.Results: The nGH of 0.53 ng/mL revealed a sensitivity of 97% (95% confidence interval [CI], 83-100%) and a specificity of 100% (95% CI, 82-100%). All 22 patients with acromegaly in remission suppressed GH to <1 ng/mL, 20/22 (91%) suppressed to <0.4 ng/mL, and 19/22 (86%) of subjects suppressed to <0.3 ng/mL (the maximum nGH measured in our healthy volunteer group).Conclusion: When using the Access Ultrasensitive hGH assay for OGTT, a cutoff of 0.53 ng/mL was found to most accurately differentiate patients with acromegaly in remission from those with active disease.

UR - http://www.scopus.com/inward/record.url?scp=84888883570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888883570&partnerID=8YFLogxK

U2 - 10.4158/EP12435.OR

DO - 10.4158/EP12435.OR

M3 - Article

VL - 19

SP - 937

EP - 945

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 6

ER -